Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
NCT05946551 · Emory University · PHASE3 · terminated · last registry update 2025-07-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated due to lack of funding.” | – | Registry record, Emory University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HRH1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-22Also stopped (terminated): University Hospital, Bordeaux, dexchlorpheniramine (Polaramine®) injection + Placebo injection (NCT02675374)
- 2026-06-04Phase 3 first posted: Brainfarma Industria Química e Farmacêutica S/A, dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg + dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg (NCT07626437)
- 2026-05-18Results posted on the registry: University of Alabama at Birmingham, Psilocybin + Diphenhydramine (NCT02037126)
- 2026-03-18Also stopped (terminated): Centre Oscar Lambret, pursuit of chemotherapy (NCT03301454)
- 2026-02-27Phase 3 first posted: Shi Tianming, Rimegepant 75mg Orally Disintegrating Tablets (ODT) + Betahistine Mesylate tablet (NCT07435090)
- 2026-02-17Results posted on the registry: Hoffmann-La Roche, Ocrelizumab + Ocrelizumab (NCT04544436)
- 2026-02-05Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), elotuzumab + placebo for elotuzumab (NCT04918147)
- 2026-01-13Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-520 + Placebo (NCT02065336)
- 2026-01-13Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-520 Injection + entecavir (NCT02738008)
- 2026-01-13Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-520 + entecavir (NCT02604212)
- 2026-01-13Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-520 + entecavir (NCT02577029)
- 2026-01-13Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-520 Injection + entecavir (NCT02604199)
- 2026-01-12Also stopped (terminated): Arrowhead Pharmaceuticals, ARC-521 Injection + antihistamine (NCT02797522)
- 2025-08-11Phase 3 first posted: Md. Hazrat Ali, ebastine + Placebo (NCT07114055)
- 2025-05-13Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06966700)
- 2025-05-09Results posted on the registry: National Cancer Institute (NCI), M7824 + Topotecan (NCT03554473)
- 2025-03-18Results posted on the registry: Prolacta Bioscience, a drug against HRH1 (NCT04433208)
- 2025-03-12Results posted on the registry: Dana-Farber Cancer Institute, Obinutuzumab + Placebo (NCT02867384)
- 2025-02-25Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), elotuzumab + placebo for elotuzumab (NCT04918147)
- 2025-02-13Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Bevacizumab (NCT06824467)
- 2025-01-13Results posted on the registry: Suven Life Sciences Limited, SUVN-G3031 + Placebo (NCT04072380)
- 2024-11-22Also stopped (withdrawn): Aalborg University, Zyclara 3.75 % Topical Cream + Prudoxin (NCT03943407)
- 2024-09-19Results posted on the registry: Covalon Technologies Inc., a drug against HRH1 (NCT06271993)
- 2024-08-09Results posted on the registry: University of Washington, Famotidine 20 MG (NCT03554291)
- 2024-08-09Also stopped (terminated): Bioprojet, BP1.3656 (NCT05240560)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision